INmune Bio (INMB) Reports Key Findings from Phase 2 MINDFuL Trial of XPro
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease
June 30, 2025 7:30 AM EDTIn the Phase 2 MINDFuL trial of XPro in patients with early Alzheimers Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a predefined population of amyloid-positive early AD patients with two or more biomarkers of inflammation (n=100), a benefit of XPro treatment over placebo was observed in cognitive, behavioral and biological endpoints.
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not... More
